Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 17/20 | 0.38 |
| ▸ | MAOA | P21397 | 15/20 | 0.38 |
| ▸ | KDM1A | O60341 | 13/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074533 | 0.82 | KDM1A (0.40) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL1577842 | 0.82 | HTR2A (0.41) | HTR2AHTR2CHTR2BMAOBMAOA | |
| Methane SCHEMBL16507862 | 0.80 | KDM1A (0.39) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL4794111 | 0.78 | KDM1A (0.38) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL746904 | 0.78 | HTR2A (0.38) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL7422826 | 0.78 | HTR2A (0.38) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL5526874 | 0.78 | KDM1A (0.38) | HTR2AHTR2CHTR2BMAOBMAOA | |
| Propane SCHEMBL23045273 | 0.75 | KDM1A (0.43) | HTR2AHTR2CHTR2BMAOBMAOA | |
| SCHEMBL9008592 | 0.75 | HTR2A (0.40) | HTR2AHTR2CHTR2BKDM1A | |
| SCHEMBL2121106 | 0.74 | KDM1A (0.34) | MAOBMAOAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | HTR2A 2476/4885HTR2C 648/4885HTR2B 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.